| |
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us for a deep dive into electronic Clinical Outcome Assessment (eCOA) systems. We'll explore the latest trends and strategies tailored for increasingly complex clinical trial environments. Learn about the current and future state of eCOA technology, potential areas for enhancement, ways to leverage effectively, and more. Register now. 
|
|
Today’s Big NewsNov 11, 2024 |
|
De-risk clinical trials with Foresight CLARITY’s ultra-sensitive MRD detection. Foresight CLARITY is IUO-ready for prospective trials through our CLIA-registered central lab.
Learn more about Foresight CLARITY™️ 
|
|
| By Nick Paul Taylor The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol Myers Squibb. |
|
|
|
By Zoey Becker Autolus' Aucatzyl has become the first CAR-T approved by the FDA without a REMS mandate. And the company is ready to hit the ground running, facing Gilead and Novartis as its competitors. |
By Fraiser Kansteiner Thermo Fisher is cutting a total of 160 jobs across three different viral vector facilities in Cambridge, Lexington and Plainville, according to a government filing in Massachusetts. In tandem with the staff reduction, Thermo Fisher also plans to shutter its facility in Lexington. |
By Gabrielle Masson Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine program. |
|
Wednesday, November 20, 2024 | 11am ET / 8am PT Join us to discover how to overcome challenges, and learn about practical solutions for scalability and safety in cell therapy manufacturing. Don't miss out, register today. 
|
|
By Conor Hale Boston Scientific aims to see whether its Farapulse platform can deliver results for patients with atrial fibrillation before they take any anti-arrhythmic medications. |
By Nick Paul Taylor Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing Evotec’s share price fall around 60% this year, Triton Partners has raised its stake in the drug discovery shop and is reportedly considering a buyout bid. |
By Fraiser Kansteiner ARS Pharmaceuticals said that Denmark’s ALK-Abelló is paying $145 million upfront for the rights to market Neffy in Europe, Canada and “other geographies outside of the U.S.” |
By Nick Paul Taylor Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs). |
By James Waldron Rapt Therapeutics had been holding out hopes that its immunology drug zelnecirnon still had a future despite facing a clinical hold, but the latest feedback from the FDA has persuaded the biotech to give up on the program. |
By Andrea Park The introduction of biologic therapies for hidradenitis suppurativa has “revolutionized” treatment for the rare inflammatory skin condition, though there’s still plenty of progress to be made, according to Spherix Global Insights. |
By Conor Hale After first claiming an FDA clearance last year for its mixed reality brain surgery navigation platform, Zeta Surgical has expanded its range with another agency clearance ahead of planned U.S. launch. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
|
Gene therapy holds the extraordinary potential to transform global health care, boasting a pipeline that has grown tremendously through the years. Download the QPS white paper for insights into the regulatory landscape for future cell and gene therapies. 
|
|
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
